Compare RemeGen Co., Ltd. with Similar Stocks
Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%
- Poor long term growth as Operating profit has grown by an annual rate -205.10% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -69.48
2
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
HKD 17,083 Million ()
NA (Loss Making)
NA
0.00%
0.58
-40.36%
6.74
Revenue and Profits:
Net Sales:
1,680 Million
(Quarterly Results - Dec 2025)
Net Profit:
1,383 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
56.42%
0%
56.42%
6 Months
-6.04%
0%
-6.04%
1 Year
329.85%
0%
329.85%
2 Years
316.64%
0%
316.64%
3 Years
175.27%
0%
175.27%
4 Years
163.62%
0%
163.62%
5 Years
8.17%
0%
8.17%
RemeGen Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
374.66%
EBIT Growth (5y)
-205.10%
EBIT to Interest (avg)
-69.48
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.11
Sales to Capital Employed (avg)
0.30
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
7.20
EV to EBIT
-17.23
EV to EBITDA
-24.43
EV to Capital Employed
4.93
EV to Sales
9.05
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-28.63%
ROE (Latest)
-47.61%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
1,679.60
679.50
147.18%
Operating Profit (PBDIT) excl Other Income
679.90
-102.00
766.57%
Interest
14.40
16.60
-13.25%
Exceptional Items
702.50
0.30
2,34,066.67%
Consolidate Net Profit
1,382.50
-110.50
1,351.13%
Operating Profit Margin (Excl OI)
404.80%
-150.20%
55.50%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 147.18% vs 10.09% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 1,351.13% vs 47.61% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
3,524.30
1,854.20
90.07%
Operating Profit (PBDIT) excl Other Income
488.60
-1,451.50
133.66%
Interest
76.30
78.50
-2.80%
Exceptional Items
694.90
1.70
40,776.47%
Consolidate Net Profit
769.60
-1,592.00
148.34%
Operating Profit Margin (Excl OI)
40.10%
-856.40%
89.65%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 90.07% vs 55.93% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 148.34% vs 4.66% in Dec 2024
About RemeGen Co., Ltd. 
RemeGen Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






